Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer

What is the Purpose of this Study?

The purpose of this study is to evaluate the safety of an investigational drug called azeliragon and determine the safest dose to treat patients with metastatic pancreatic cancer. The study will examine the effects of azeliragon on patients and their pain (if any). Azeliragon may have the potential to slow down the development and growth of pancreatic cancer cells in the body; it will be provided to participants as a hard gelatin capsule.

Eligibility

Patient must have histologically confirmed locally advanced or metastatic adenocarcinoma of the pancreas for which potential curative measures, such as resection of an isolated metastasis, are not available.
Patient should have previously been treated with a Gemcitabine/Abraxane or FOLFIRINOX- based regimen.
Toxicity from prior chemotherapy other than alopecia has recovered to Grade ≤ 1 (CTCAE 1.0) or are at baseline (such as stable G2 neuropathy).
Male or non-pregnant and non-lactating female and ≥ 18 to ≤ 80 years of age.

Inclusion Criteria:

Patient must have histologically confirmed locally advanced or metastatic adenocarcinoma of the pancreas for which potential curative measures, such as resection of an isolated metastasis, are not available.
Patient should have previously been treated with a Gemcitabine/Abraxane or FOLFIRINOX- based regimen.
Toxicity from prior chemotherapy other than alopecia has recovered to Grade ≤ 1 (CTCAE 1.0) or are at baseline (such as stable G2 neuropathy).
Male or non-pregnant and non-lactating female and ≥ 18 to ≤ 80 years of age.
Patient has adequate biological parameters as demonstrated by the following blood counts at Screening (obtained ≤ 14 days prior to enrollment) and at Baseline-Day 0: Absolute neutrophil count (ANC) ≥ 1.0 × 109/L; Platelet count ≥ 75,000/mm3 (75 × 109/L); Hemoglobin (Hgb) ≥ 9 g/dL without transfusion or growth factor support
Patient has the following blood chemistry levels at Screening (obtained ≤ 14 days prior to enrollment) and at Baseline-Day 0:
AST (SGOT), ALT (SGPT) ≤ 2.5 × upper limit of normal range (ULN), unless liver metastases are present, then ≤ 5 x ULN is acceptable. Total bilirubin ≤ 1.5 × ULN.
Estimated creatinine clearance of > 60 mL/min (per Cockroft-Gault formula)
Patient has ECOG performance status of ≤ 2
Patient has been informed about the nature of the study, and has agreed to participate in the study, and signed the Informed Consent Form prior to participation in any study-related activities.

Exclusion Criteria:

Patient has a life expectancy, per investigator assessment, of less than 3 months.
Patient has experienced an increase of ECOG to > 2 between Screening and the time of first dose with study drug.
Patient has active, uncontrolled bacterial, or fungal infection(s) requiring systemic therapy.
Patients receiving CYP 2C8 inhibitors noted in Section 5.3 of the protocol.
Patient has a concomitant serious medical or psychiatric illness that, in the opinion of the investigator, could compromise the patient's safety or the study data integrity.
Patient is unwilling or unable to comply with study procedures, including, but not limited to self-administration of oral medication.
Patients with a gastrointestinal condition that could interfere with swallowing or absorption.
Females of childbearing potential who are sexually active or males with female partners of childbearing potential, where either the female or the male is unwilling to use a highly effective method of contraception during the trial and for 6 months after the last administration of study drug.
Patients with concurrent participation in another interventional clinical trial or use of another investigational agent within 14 days of starting study drug. Patients who are participating in non-interventional clinical trials (e.g., quality of life, imaging, observational, follow-up studies, etc.) are eligible, regardless of the timing of participation.

Show less

Where can I participate?

Cedars-Sinai Cancer at Beverly Hills (THO) : Abrahm Levi
Cedars-Sinai Cancer at SOCC : Abrahm Levi

More about this Clinical Trial

What is the full name of this clinical trial?

CAN-201: A Phase I/II Open Label Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer

Study Details

Disease Type/Condition

Pancreas

Principal Investigator

Hendifar, Andrew

Co-Investigators

Arsen Osipov, David Hoffman, Jeremy Lorber, Jun Gong, Kamya Sankar, Kevin Scher

Age Group

Adult

Phase

I/II

IRB Number

STUDY00002298

ClinicalTrials.gov ID

NCT05766748

Key Eligibility

ClinicalTrials.gov

How do I learn more about this study?

Name

Abrahm Levi

Abrahm.Levi@cshs.org